Skip to main content
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: Am J Med Sci. 2015 Oct;350(4):302–307. doi: 10.1097/MAJ.0000000000000556

Figure 2. Change in 25(OH)D levels in SLE patients with and without increase in % FMD with D3 therapy.

Figure 2

SLE patients randomized to take low or adequate D3 doses daily for 16 weeks had FMD measured at baseline and 16 weeks. Results are reported as change in 25(OH)D levels over 16 weeks in those who had increases or no increases in FMD during the study period.